J147: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 1: Line 1:
'''J147''' is an experimental drug with reported effects against both [[Alzheimer's disease]] and ageing in mouse models of accelerated aging. The drug was developed at the [[Salk Institute for Biological Studies]] by a team led by David Schubert.
== J147 ==


== History ==
[[File:J147_structure.png|thumb|right|Chemical structure of J147]]


J147 was first synthesized in 2011. The development of J147 was based on the examination of cellular pathways in old human brain cells. Instead of focusing on the pathologies of Alzheimer's disease, the team at Salk Institute decided to screen for molecules that targeted the major pathways of aging.
'''J147''' is a synthetic compound that has been investigated for its potential therapeutic effects in [[neurodegenerative diseases]], particularly [[Alzheimer's disease]]. It was developed by researchers at the [[Salk Institute for Biological Studies]] and has shown promise in preclinical studies for its ability to improve cognitive function and protect against [[neurodegeneration]].
 
== Chemical Properties ==
 
J147 is a derivative of the natural product [[curcumin]], which is found in the spice [[turmeric]]. The chemical structure of J147 is designed to enhance its [[bioavailability]] and [[blood-brain barrier]] penetration compared to curcumin. The compound is characterized by its ability to modulate multiple [[biological pathways]] associated with aging and neurodegeneration.


== Mechanism of Action ==
== Mechanism of Action ==


J147 works by binding to a protein found in mitochondria, the energy-generating powerhouses of cells, leading to an array of beneficial effects. It enhances the function of mitochondria, providing neurons with protection against age-associated declines in energy production.
J147 has been shown to interact with several molecular targets, including the [[mitochondrial ATP synthase]], which plays a crucial role in cellular energy production. By modulating this enzyme, J147 is thought to enhance [[mitochondrial function]] and reduce the production of [[reactive oxygen species]], thereby protecting neurons from oxidative stress.
 
Additionally, J147 has been reported to increase levels of [[brain-derived neurotrophic factor]] (BDNF), a protein that supports the survival and growth of neurons. This action may contribute to its neuroprotective and cognitive-enhancing effects.


== Research and Development ==
== Potential Therapeutic Applications ==
 
J147 is primarily being studied for its potential use in treating [[Alzheimer's disease]]. In animal models, it has been shown to improve memory and cognitive function, reduce [[amyloid-beta]] levels, and decrease [[inflammation]] in the brain. These findings suggest that J147 could be a promising candidate for further development as a treatment for Alzheimer's disease.


In mouse models of accelerated aging, J147 improved memory and prevented the loss of neuronal cells. It also extended the lifespan of healthy mice. In 2018, the team at Salk Institute discovered that the drug binds to a protein called ATP synthase, specifically inhibiting its activity in a subunit called c-Fo.
Beyond Alzheimer's, J147 may have applications in other [[age-related cognitive disorders]] and [[neurodegenerative diseases]], although more research is needed to fully understand its therapeutic potential and safety profile.


== Clinical Trials ==
== Research and Development ==


As of 2021, J147 is in Phase 1 clinical trials for Alzheimer's disease. The trials are being conducted by a company called Abrexa Pharmaceuticals.
Research on J147 is ongoing, with studies focusing on its efficacy, safety, and mechanism of action. Clinical trials will be necessary to determine its potential as a therapeutic agent in humans. The development of J147 is part of a broader effort to find new treatments for neurodegenerative diseases by targeting the underlying mechanisms of aging.


== See Also ==
== Related Pages ==


* [[Alzheimer's disease]]
* [[Alzheimer's disease]]
* [[ATP synthase]]
* [[Neurodegeneration]]
* [[Mitochondria]]
* [[Curcumin]]
* [[Salk Institute for Biological Studies]]
* [[Mitochondrial function]]
* [[Brain-derived neurotrophic factor]]


[[Category:Neuropharmacology]]
[[Category:Experimental drugs]]
[[Category:Experimental drugs]]
[[Category:Alzheimer's disease]]
[[Category:Ageing]]
{{stub}}

Latest revision as of 03:43, 13 February 2025

J147[edit]

Chemical structure of J147

J147 is a synthetic compound that has been investigated for its potential therapeutic effects in neurodegenerative diseases, particularly Alzheimer's disease. It was developed by researchers at the Salk Institute for Biological Studies and has shown promise in preclinical studies for its ability to improve cognitive function and protect against neurodegeneration.

Chemical Properties[edit]

J147 is a derivative of the natural product curcumin, which is found in the spice turmeric. The chemical structure of J147 is designed to enhance its bioavailability and blood-brain barrier penetration compared to curcumin. The compound is characterized by its ability to modulate multiple biological pathways associated with aging and neurodegeneration.

Mechanism of Action[edit]

J147 has been shown to interact with several molecular targets, including the mitochondrial ATP synthase, which plays a crucial role in cellular energy production. By modulating this enzyme, J147 is thought to enhance mitochondrial function and reduce the production of reactive oxygen species, thereby protecting neurons from oxidative stress.

Additionally, J147 has been reported to increase levels of brain-derived neurotrophic factor (BDNF), a protein that supports the survival and growth of neurons. This action may contribute to its neuroprotective and cognitive-enhancing effects.

Potential Therapeutic Applications[edit]

J147 is primarily being studied for its potential use in treating Alzheimer's disease. In animal models, it has been shown to improve memory and cognitive function, reduce amyloid-beta levels, and decrease inflammation in the brain. These findings suggest that J147 could be a promising candidate for further development as a treatment for Alzheimer's disease.

Beyond Alzheimer's, J147 may have applications in other age-related cognitive disorders and neurodegenerative diseases, although more research is needed to fully understand its therapeutic potential and safety profile.

Research and Development[edit]

Research on J147 is ongoing, with studies focusing on its efficacy, safety, and mechanism of action. Clinical trials will be necessary to determine its potential as a therapeutic agent in humans. The development of J147 is part of a broader effort to find new treatments for neurodegenerative diseases by targeting the underlying mechanisms of aging.

Related Pages[edit]